 STOCKHOLM, Oct. 7, 2021 PRNewswire -- Calliditas Therapeutics AB Nasdaq: CALT Nasdaq Stockholm: CALTX Calliditas today announced that the company now controls 100 of the share capital of Genkyotex SA Genkyotex, after the completion of a centralized squeeze out offer to all minority shareholders. Genkyotexs lead product candidate, setanaxib, is a first-in-class NOX inhibitor that targets NOX 1 and NOX 4, which are major drivers of fibrogenesis in multiple organs. 